JNNP podcast

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on peripheral nerve disease research and practice from James Overell, consultant neurologist, Institute of Neurological Sciences, Glasgow.They discuss treatment for CIDP, differences in neuropathy prevention and management in type 1 and type 2 diabetes, chronic inflammatory neuropathies, and hereditary motor sensory neuropathies.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here https://soundcloud.com/tags/abn%202013.

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on peripheral nerve disease research and practice from James Overell, consultant neurologist, Institute of Neurological Sciences, Glasgow.They discuss treatment for CIDP, differences in neuropathy prevention and management in type 1 and type 2 diabetes, chronic inflammatory neuropathies, and hereditary motor sensory neuropathies.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here https://soundcloud.com/tags/abn%202013.

Where are we with stem cell treatments for stroke and Parkinson’s disease? At the Association of British Neurologists’ recent annual meeting in Glasgow, Neil Scolding, director of the Bristol Institute of Clinical Neurosciences, spoke to Keith Muir, Institute of Neuroscience and Psychology, Univeristy of Glasgow, and Roger Barker, John van Geest Centre for Brain Repair, University of Cambridge, about current research, and the expensive, unproven treatments already on the market.And using enlarged perivascular spaces to identify arteriopathy in intracerabral haemorrhage. Nick Ward, JNNP associate editor, asks David Werring, reader in neurology, UCL Institute of Neurology, what his MRI study reveals.See also:Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study http://bit.ly/12iZWieStriatal cell transplants for Huntington’s disease: where are we now? http://bit.ly/18InWwa

Where are we with stem cell treatments for stroke and Parkinson’s disease? At the Association of British Neurologists’ recent annual meeting in Glasgow, Neil Scolding, director of the Bristol Institute of Clinical Neurosciences, spoke to Keith Muir, Institute of Neuroscience and Psychology, Univeristy of Glasgow, and Roger Barker, John van Geest Centre for Brain Repair, University of Cambridge, about current research, and the expensive, unproven treatments already on the market.And using enlarged perivascular spaces to identify arteriopathy in intracerabral haemorrhage. Nick Ward, JNNP associate editor, asks David Werring, reader in neurology, UCL Institute of Neurology, what his MRI study reveals.See also:Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study http://bit.ly/12iZWieStriatal cell transplants for Huntington’s disease: where are we now? http://bit.ly/18InWwa

This month Connie Marras, assistant professor of neurology, University of Toronto, talks us through her review of Parkinson’s disease subtypes.What definitions do we have so far, what could they tell us about the condition, and how can we get them incorporated into research more?See also:Parkinson’s disease subtypes: lost in translation? http://bit.ly/12mKxYL

This month Connie Marras, assistant professor of neurology, University of Toronto, talks us through her review of Parkinson’s disease subtypes.What definitions do we have so far, what could they tell us about the condition, and how can we get them incorporated into research more?See also:Parkinson’s disease subtypes: lost in translation? http://bit.ly/12mKxYL

In this special edition of the podcast, JNNP associate editor Nick Ward looks into some of the latest research into stroke.Tracking cognitive function in those recovering from stroke in routine. Owen White, associate professor, Department of Neurology, Royal Melbourne Hospital, describes how assessing ocular motor deficits is a sensitive way of doing this. Furthermore, he describes the computerised programme he’s come up with to treat these, and why he believes doing so will lead to improvement in both sensory and motor areas.Tatu Kauranen has also been looking into assessing cognitive function, and discusses the value of this in predicting return to work after stroke.And Peter Rothwell explains why it’s safe and effective to treat those who’ve had an acute minor stroke as outpatients.See also:Stroke: mechanisms, stratification and implementation http://bit.ly/16o2YmFIschaemic stroke: the ocular motor system as a sensitive marker for motor and cognitive recovery http://bit.ly/ZmHFdTCould saccadic function be a useful marker of stroke recovery? http://bit.ly/10VojTzThe severity of cognitive deficits predicts return to work after a first-ever ischaemic stroke http://bit.ly/ZVjeJgReturn to work after stroke: the role of cognitive deficits http://bit.ly/10VorCvFeasibility, safety and cost of outpatient management of acute minor ischaemic stroke: a population-based study http://bit.ly/11VFocMIs the outpatient management of acute minor stroke feasible and safe? http://bit.ly/11VFocMThe JNNP stroke special edition jnnp.bmj.com/content/84/3Follow Nick Ward’s lab at UCL on Twitter http://bit.ly/18cNstj

In this special edition of the podcast, JNNP associate editor Nick Ward looks into some of the latest research into stroke.Tracking cognitive function in those recovering from stroke in routine. Owen White, associate professor, Department of Neurology, Royal Melbourne Hospital, describes how assessing ocular motor deficits is a sensitive way of doing this. Furthermore, he describes the computerised programme he’s come up with to treat these, and why he believes doing so will lead to improvement in both sensory and motor areas.Tatu Kauranen has also been looking into assessing cognitive function, and discusses the value of this in predicting return to work after stroke.And Peter Rothwell explains why it’s safe and effective to treat those who’ve had an acute minor stroke as outpatients.See also:Stroke: mechanisms, stratification and implementation http://bit.ly/16o2YmFIschaemic stroke: the ocular motor system as a sensitive marker for motor and cognitive recovery http://bit.ly/ZmHFdTCould saccadic function be a useful marker of stroke recovery? http://bit.ly/10VojTzThe severity of cognitive deficits predicts return to work after a first-ever ischaemic stroke http://bit.ly/ZVjeJgReturn to work after stroke: the role of cognitive deficits http://bit.ly/10VorCvFeasibility, safety and cost of outpatient management of acute minor ischaemic stroke: a population-based study http://bit.ly/11VFocMIs the outpatient management of acute minor stroke feasible and safe? http://bit.ly/11VFocMThe JNNP stroke special edition jnnp.bmj.com/content/84/3Follow Nick Ward’s lab at UCL on Twitter http://bit.ly/18cNstj

The problem of those with Parkinson’s disease becoming addicted to dopamine replacement therapy is well know, but it’s also now emerging that some patients have trouble coming of dopamine agonists.Margarita Pondal, from the Movement Disorders Centre, University of Toronto, talks us through her study looking at the prevalence of the syndrome, and the patients who are most likely to be affected.See also:Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic http://bit.ly/12VwBI6Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine ‘switch’ http://bit.ly/18cN2Tu

The problem of those with Parkinson’s disease becoming addicted to dopamine replacement therapy is well know, but it’s also now emerging that some patients have trouble coming of dopamine agonists.Margarita Pondal, from the Movement Disorders Centre, University of Toronto, talks us through her study looking at the prevalence of the syndrome, and the patients who are most likely to be affected.See also:Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic http://bit.ly/12VwBI6Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine ‘switch’ http://bit.ly/18cN2Tu

Cognitive impairment in those with epilepsy is common. Adam Zeman, professor of cognitive and behavioural neurology, University of Exeter, ask Christoph Helmstaedter, associate professor for clinical neuropsychology, the University Clinic of Epileptology in Bonn, about the association, including the effects antiepileptic drugs can have on cognition.Further resources:Helmstaedter C, Witt JA. Clinical neuropsychology in epilepsy: theoretical and practical issues. Handb Clin Neurol. 2012;107:437-59.Neuropsychology in the Care of People with Epilepsy, in the Progress in Epileptic Disorders Series. John Libbey, 2011.Christoph Helmstaedter spoke on this topic at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Cognitive impairment in those with epilepsy is common. Adam Zeman, professor of cognitive and behavioural neurology, University of Exeter, ask Christoph Helmstaedter, associate professor for clinical neuropsychology, the University Clinic of Epileptology in Bonn, about the association, including the effects antiepileptic drugs can have on cognition.Further resources:Helmstaedter C, Witt JA. Clinical neuropsychology in epilepsy: theoretical and practical issues. Handb Clin Neurol. 2012;107:437-59.Neuropsychology in the Care of People with Epilepsy, in the Progress in Epileptic Disorders Series. John Libbey, 2011.Christoph Helmstaedter spoke on this topic at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Robin Carhart-Harris, post-doctoral researcher, Division of Brain Sciences, Imperial College London, explains his hypothesis on the shared neurobiology of psychosis, psychedelic states and spontaneous spiritual experiences to Peter Halligan, professor in the School of Psychology, Cardiff University.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

Robin Carhart-Harris, post-doctoral researcher, Division of Brain Sciences, Imperial College London, explains his hypothesis on the shared neurobiology of psychosis, psychedelic states and spontaneous spiritual experiences to Peter Halligan, professor in the School of Psychology, Cardiff University.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.

What relevance does consciousness have for our understanding of mental conditions? Geraint Rees, deputy head of the UCL Faculty of Brain Sciences, tells Peter Halligan, professor in the School of Psychology, Cardiff University, about his work in the area.This podcast was recorded at the British NeuroPsychiatry Association’s 2013 AGM. For more information on the association and next year’s meeting, see bnpa.org.uk.